Siemens Healthineers shows resilient performance despite COVID-19 pandemic

Erlangen, Germany|2020-08-02

Siemens Healthineers AG today announced its results for the third quarter of fiscal year 2020 that ended June 30, 2020.

Q3 Fiscal Year 2020

  • Revenue down 6.9% year-over-year on a comparable basis due to COVID-19
  • Comparable revenue decline of 3.3% in Imaging, Advanced Therapies with comparable decline of 1.8%
  • Service with slight comparable revenue growth, stabilizing business
  • Equipment book-to-bill ratio at 0.94
  • Diagnostics with comp. revenue decline of 15.9% due to lower testing for routine care, significantly impacting profitability
  • Adjusted EBIT margin at 13.9%, 120 bps below prior-year quarter
  • Adjusted basic earnings per share down 21% to €0.30
  • Q3 free cash flow increases 48% year-over-year to €336 million
  • Comparable revenue growth expected to be broadly flat in fiscal year 2020; adjusted basic earnings per share expected to be between €1.54 and €1.62. This is based on the assumption that the current business environment will not deteriorate again

Bernd Montag, CEO of Siemens Healthineers AG:
"The Siemens Healthineers team has been making an extraordinary contribution to overcoming this historic crisis for months – at our customers’ sites, in production, at our locations around the world and through rapid innovation. The development in the third quarter underscores the resilience of our business. For the fourth quarter, we are anticipating a significant improvement of our business performance compared to the third quarter."



Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion. Further information is available at www.siemens-healthineers.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a various risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the forward-looking statement. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.

The information contained in this document is provided as of the date of its publication and is subject to change without notice.

Please find further explanations regarding our financial key performance indicators in chapter „A.2 Financial performance system“ and in the notes to the consolidated financial statements note 29 „Segment information“ in the Annual Report 2019 of Siemens Healthineers. Additional information on reconciliations is also included in the Analyst Presentation. These documents are available under the following internet link https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications.


Matthias Kraemer
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 9131 843383
matthias.kraemer@siemens-healthineers.com

Philipp Grontzki
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 152 03350194
philipp.grontzki@siemens-healthineers.com

Ulrich Kuenzel
Karlheinz Kaske Straße 5
91052 Erlangen
Germany

+49 162 2433492
ulrich.kuenzel@@siemens-healthineers.com